Upfront Briefing
Moderna has settled its COVID-19 vaccine patent litigation with Arbutus and Genevant Sciences (Roivant/Pontifax), agreeing to pay up to $2.25 billion. This big legal headline swaps courtroom uncertainty for a modelable price tag.
Meanwhile, Teva and Blackstone Life Sciences lined up $400M to advance duvakitug (TL1A), and Sanofi signed a $1.5B global licensing deal for Sino Biopharm’s first-in-class JAK/ROCK asset (pipeline shopping, but make it expensive).
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,816.6 |
(0.9%) |
(0.4%) |
| Nasdaq 100 |
24,720.1 |
(1.1%) |
(2.1%) |
| Russell 2000 |
2,608.4 |
(1.8%) |
+5.1% |
| Healthcare (XLV) |
156.7 |
(1.1%) |
+1.3% |
| Biotech (XBI) |
123.5 |
(2.4%) |
+1.3% |
| Nasdaq Biotech (NBI) |
5,874.6 |
(2.3%) |
+2.9% |
| Clinical Trials (BBC) |
41.2 |
(2.3%) |
+6.9% |
|
-
Risk-off tape: escalating Middle East conflict risk pushed oil/“inflation fear” back into the macro, lifting volatility and pressuring equities into the close.
-
Biotech took the extra beta hit: XBI and NBI underperformed as investors de-risked higher-duration growth and de-levered risk buckets.
-
Market data: U.S. close Tue 03-Mar-2026.
The Big 3
|
1
|
Moderna settles COVID-19 vaccine patent suit for up to $2.25B
|
-
Moderna has settled its COVID-19 vaccine patent litigation with Arbutus and Roivant (Genevant), agreeing to pay up to $2.25 billion.
-
Why it matters:
This converts an open-ended LNP IP liability into a finite, timeable cash obligation ($950M upfront in July + potential $1.3B contingent), while removing ongoing royalty exposure — materially improving Moderna’s ability to underwrite its next-gen vaccine pipeline and cash runway with less litigation-driven tail risk.
-
Source:
STAT
-
More:
Endpoints
|
|
2
|
Teva, Blackstone Life Sciences secure $400M for duvakitug
|
-
Teva and Blackstone Life Sciences announced a $400 million funding agreement to advance duvakitug (TL1A), a Sanofi-partnered asset.
-
Why it matters:
This is “late-stage financing-as-a-structure”: Teva funds Phase 3 without issuing equity, while giving BXLS milestones + low single-digit royalties. For investors, it de-risks execution funding but creates a new economic claim on what could be a large IBD asset — a trade-off that signals Teva’s urgency to build an innovative revenue engine beyond the generics base.
-
Source:
Endpoints
-
More:
PR
|
|
3
|
Sanofi inks $1.5B global licensing deal with Sino Biopharm
|
-
Sanofi has entered a $1.5 billion global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset, expanding its immunology pipeline.
-
Why it matters:
Sanofi is effectively paying to buy time: $135M upfront with a $1.4B milestone stack for a first-in-class oral JAK/ROCK program, reinforcing the pattern of global pharma pulling differentiated China-origin assets into Western pipelines. For investors, the structure implies Sanofi sees a credible path to multi-indication value — and it raises the bar (and price) for competitive hematology/immunology in-licensing.
-
Source:
Fierce Pharma
-
More:
Fierce Biotech
|
Everything Else that broke
- March FDA PDUFA calendar includes Rocket gene therapy. — BioCentury
- J&J's nipocalimab gets FDA Fast Track for lupus. — PR
-
Theravance Biopharma Phase 3 CYPRESS miss triggers strategic review + major cost cuts. — PR
- BioVersys publishes BV100 Phase 1 data in AAC journal. — PR
- Bavarian Nordic seeks new CEO as Chaplin plans exit. — BioCentury
- Keytruda remains top seller as GLP-1s gain ground. — BioSpace
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly
⬇️
|
M&A / BD&L
- Sanofi inks $1.5B global licensing deal with Sino Biopharm. — Fierce Pharma
- Teva, Blackstone Life Sciences secure $400M for duvakitug. — Endpoints
- Astellas invests in Vir's bispecific masking technology. — BioCentury
- MGI Tech acquires STOmics, CycloneSEQ for omics offering. — PR
VC / Private Financings
-
Prolium Bioscience launches with a $50M Series A to advance PRO-203 (CD20xCD3) in severe autoimmune disease — led by RTW Investments (other investors not disclosed). —
PR
-
Persevere Therapeutics launches and announces first close of a Seed round (syndicate not disclosed). —
BioSpace
IPOs / Follow-Ons
- No notable IPOs / follow-ons in the last 24 hours.
Academic Corner
- In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial. — Nature Medicine
- LLM-assisted systematic review of large language models in clinical medicine. — Nature Medicine
- Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. — Nature Medicine
|
